Withholding or continuing beta-blocker treatment before dipyridamole myocardial perfusion imaging for the diagnosis of coronary artery disease? A randomized clinical trial

• Published in: Daru Vol. 21; no. 1; p. 1
• Main Authors: Fallahi, Babak, Beiki, Davood, Akbarpour, Saeed, Gholamrezanezhad, Ali, Fard-Esfahani, Armaghan, Akhzari, Fariba, Izadyar, Sina, Esmaeli, Javad, Saghari, Mohsen, Eftekhari, Mohammad
• Format: Journal Article
• Language: English
• Published: New York Springer Nature B.V 01.01.2013
• Subjects: Cardiovascular disease; Coronary vessels; Defects; Drug dosages; Heart attacks; Heart rate; Methods; Patients
• ISSN: 1560-8115; 2008-2231

Although it has been shown that acute beta-blocker administration may reduce the presence or severity of myocardial perfusion defects with dipyridamole stress, little information is available about the potential effect of chronic beta-blocker treatment on the sensitivity of dipyridamole myocardial perfusion imaging (DMPI). As a randomized clinical trial, 120 patients (103 male and 17 female) with angiographically confirmed CAD who were on long-term beta blocker therapy (≥3 months) enrolled in a randomized clinical trial study. The patients were allocated into two groups: Group A (n=60) in whom the beta-blocker agent was discontinued for 72h before DMPI and Group B (n=60) without discontinuation of beta-blockers prior to DMPI. No significant difference was noted between the groups concerning age, sex, type of the injected radiotracer and number of involved coronary vessels. The mean rank of total perfusion scores for whole myocardium (irrespective of reversibility or irreversibility) in group B was not significantly different from that of group A, (65.75 vs. 55.25, P=0.096).